Investigational drug for returning CD19-positive blood cancer
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a new medicine called LV009 for people with certain blood cancers (like leukemia or lymphoma) that have come back or not responded to treatment. The goal is to see if LV009 is safe and works against these cancers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your blood cancer must have returned or not responded to previous treatments.
- Your cancer cells must have a marker called CD19.
- You need to be in fairly good health, with your heart, liver, kidneys, and lungs working well enough.
- Your blood cell counts must be above certain minimums.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental treatment called LV009 for people with certain types of blood cancers that have come back or not responded to previous treatments. The treatment targets a protein called CD19 found on cancer cells.
This trial tests a new treatment called LV009, a type of CAR-T cell therapy, for people with certain blood cancers (like leukemia or lymphoma) that have CD19 on their cells. The therapy uses your own immune cells to fight the cancer.
This study tests a new cell-based treatment called LV009 in people with certain blood cancers, autoimmune diseases, or antibodies that make transplants difficult. The treatment is meant to fight the disease or reduce harmful antibodies, possibly helping patients who have not responded to other therapies.
This early-phase trial tests an investigational cell therapy called LVIVO-TaVec122 for people with certain blood cancers (lymphoma or leukemia) that have come back or not responded to previous treatments. The goal is to see if this new treatment is safe and works for you.
This trial tests a new experimental medicine (SYS6055 injection) for people with B-cell blood cancers (leukemia or lymphoma) that have come back or not responded to standard treatments. The goal is to see if it is safe and how well it works against cancer cells that have the CD19 marker.
This study tests a new therapy called RS001 for people with B-cell lymphoma or B-cell leukemia that has not gotten better or has returned after treatment. It targets a marker called CD19 on cancer cells, and the goal is to see if it can help control the cancer.
Hear when a new CD19+ Relapse/Refractory B-ALL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.